Antibody production capacity after COVID-19 vaccination in immune-mediated neuromuscular diseases under immunotherapy-Reference-Cited by-同舟云学术

Antibody production capacity after COVID-19 vaccination in immune-mediated neuromuscular diseases under immunotherapy

Published:2023 Issue:3 Volume:63 Page:145-151
ISSN:0009-918X
Container-title:Rinsho Shinkeigaku
language:en
Short-container-title:Rinsho Shinkeigaku

Author:

Kaido Misako¹,Kajiyama Yuta²,Sasaki Shinya³,Saitou Takako³,Esa Yoshiki⁴,Watanabe Yushi⁴,Fujimura Harutoshi⁴,Kobayashi Junya⁴

Affiliation:

1. Department of Clinical genetics, Sakai City Medical Center

2. Department of Neurology, Osaka University Graduate School of Medicine

3. Department of Clinical Laboratory, Sakai City Medical Center

4. Department of Neurology, Sakai City Medical Center

Publisher

Societas Neurologica Japonica

Subject

Neurology (clinical)

Link

https://www.jstage.jst.go.jp/article/clinicalneurol/63/3/63_cn-001825/_pdf

Reference15 articles.

1. 1) Coronavirus Pandemic (COVID-19). Our World in Data [Internet]. England and Wales: Our World in Data [cited 2022 Dec 6]. Available from: https://ourworldindata.org/coronavirus

2. 2) 新型コロナウイルス感染症（COVID-19）への対応について．日本脳神経学会ホームページ［Internet］．東京：日本脳神経学会［cited 2022 Nov 27］．Available from: https://www.neurology-jp.org/covid/

3. 3) Day AL, Winthrop KL, Curtis JR. The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. Cleve Clin J Med 2020;87:695-703.

4. 4) Arnold J, Winthrop K, Emery P. COVID-19 vaccination and ‍antirheumatic therapy. Rheumatology (Oxford) 2021;60:3496-3502.

5. 5) Marsh EB, Kornberg M, Kessler K, et al. COVID-19 and vaccination in the setting of neurologic disease: an emerging issue in neurology. Neurology 2021;97:720-728.